Regeneron (REGN)

343.34 -0.90 (0.26%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (2/6/20 *Est.)
- Conference (12/3/2019)

Latest Headlines

Form 4 REGENERON PHARMACEUTICAL For: Nov 12 Filed by: BROWN MICHAEL S November 13, 2019 4:12 PM - SEC Filing Form 4 REGENERON PHARMACEUTICAL For: Nov 08 Filed by: STAHL NEIL November 12, 2019 4:06 PM - SEC Filing Regeneron Announces Upcoming Investor Conference Presentations November 12, 2019 7:30 AM - PR NewsWire UPDATE: SunTrust Starts Regeneron Pharma (REGN) at Hold November 12, 2019 4:32 AM - StreetInsider Form 4 REGENERON PHARMACEUTICAL For: Nov 08 Filed by: GOLDSTEIN JOSEPH L November 8, 2019 5:03 PM - SEC Filing Citi Upgrades Regeneron Pharma (REGN) to Buy November 6, 2019 4:18 PM - StreetInsider Regeneron to Report Results from CD20xCD3 and BCMAxCD3 Bispecifics and C5 Antibody Programs at ASH Annual meeting November 6, 2019 9:00 AM - PR NewsWire Regeneron Pharma (REGN) PT Lowered to $430 at Oppenheimer November 6, 2019 7:46 AM - StreetInsider Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer November 6, 2019 7:00 AM - PR NewsWire Regeneron Pharma (REGN) PT Raised to $358 at BMO Capital November 6, 2019 6:53 AM - StreetInsider Regeneron Pharma (REGN) PT Raised to $387 at Morgan Stanley November 6, 2019 6:37 AM - StreetInsider Regeneron Pharma (REGN) PT Lowered to $400 at Cantor Fitzgerald November 6, 2019 6:35 AM - StreetInsider Regeneron Pharma (REGN) PT Raised to $340 at Credit Suisse November 6, 2019 6:22 AM - StreetInsider Regeneron Pharma (REGN) PT Raised to $352 at BMO Capital November 5, 2019 3:43 PM - StreetInsider Regeneron Pharma (REGN) PT Raised to $352 at Cowen November 5, 2019 3:42 PM - StreetInsider Regeneron Pharma (REGN) PT Raised to $340 at Canaccord Genuity November 5, 2019 1:56 PM - StreetInsider Pre-Open 11/05: (EVER) (INO) (CHGG) Higher (MYGN) (SNCR) (SHAK) Lower (more...) November 5, 2019 9:24 AM - StreetInsider Inovio Pharma (INO) Reports Positive Interim Data from Ph. 2 Study (NCT03491683) with INO-5401 in Combination with PD-1 Inhibitor Libtayo (cemiplimab) November 5, 2019 8:11 AM - StreetInsider Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab) November 5, 2019 8:00 AM - PR NewsWire Form 10-Q REGENERON PHARMACEUTICAL For: Sep 30 November 5, 2019 7:49 AM - SEC Filing Form 8-K REGENERON PHARMACEUTICAL For: Nov 05 November 5, 2019 7:36 AM - SEC Filing Regeneron (REGN) Reports Updates on Phase 3 Libtayo (cemiplimab) Development Program in Advanced NSCLC November 5, 2019 6:44 AM - StreetInsider Regeneron Provides Updates on Phase 3 Libtayo® (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer November 5, 2019 6:40 AM - PR NewsWire Regeneron (REGN) Tops Q3 EPS by 31c, Offers FY Guidance November 5, 2019 6:32 AM - StreetInsider Regeneron Reports Third Quarter 2019 Financial and Operating Results November 5, 2019 6:30 AM - PR NewsWire Sanofi : Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis October 29, 2019 8:16 AM - StreetInsider Regeneron (REGN) Announces Dupixent is Now Approved in European Union for Severe Chronic Rhinosinusitis with Nasal Polyposis October 29, 2019 8:15 AM - StreetInsider Dupixent® (dupilumab) Now Approved in European Union for Severe Chronic Rhinosinusitis with Nasal Polyposis October 29, 2019 8:15 AM - PR NewsWire Regeneron Ranked #2 in Science Magazine's Top Biopharma Companies to Work For October 25, 2019 7:05 AM - PR NewsWire Regeneron Colleagues Support 150 Community Organizations During Third Annual Day for Doing Good October 25, 2019 7:00 AM - PR NewsWire Regeneron Announces Upcoming Investor Conference Presentations October 18, 2019 8:30 AM - PR NewsWire UPDATE: BofA/Merrill Lynch Reinstates Regeneron Pharma (REGN) at Neutral October 16, 2019 4:33 PM - StreetInsider Bernstein Reinstates Regeneron Pharma (REGN) at Market Perform October 14, 2019 6:58 AM - StreetInsider Regeneron to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2019 October 10, 2019 9:30 AM - PR NewsWire Form CT ORDER REGENERON PHARMACEUTICAL October 8, 2019 2:00 PM - SEC Filing Novartis' Beovu Label a Positive for Regeneron Pharma (REGN) - BMO October 8, 2019 12:24 PM - StreetInsider Regeneron Pharma (REGN) PT Lowered to $320 at Canaccord Genuity October 8, 2019 11:35 AM - StreetInsider UPDATE: Guggenheim Upgrades Regeneron Pharma (REGN) to Buy September 23, 2019 7:00 AM - StreetInsider Regeneron (REGN), Sanofi (SNY) Report Publication of Results from Two Positive Phase 3 Trials of Dupixent (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps September 20, 2019 7:01 AM - StreetInsider The Lancet Publishes Results from Two Positive Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) September 20, 2019 6:59 AM - PR NewsWire Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis   September 20, 2019 6:49 AM - StreetInsider Regeneron (REGN) Announces CHMP Recommended Approval of Dupixent for Severe Chronic Rhinosinusitis with Nasal Polyposis September 20, 2019 6:44 AM - StreetInsider CHMP Recommends Approval of Dupixent® (dupilumab) for Severe Chronic Rhinosinusitis with Nasal Polyposis September 20, 2019 6:44 AM - PR NewsWire Educational Campaign Helps Teens and Their Caregivers Tackle Everyday Challenges of Living with Moderate-to-severe Atopic Dermatitis September 18, 2019 6:59 AM - PR NewsWire Regeneron Debuts on Prestigious Dow Jones Sustainability World Index of Most Sustainable Companies September 17, 2019 7:00 AM - PR NewsWire Form 4 REGENERON PHARMACEUTICAL For: Sep 10 Filed by: Sanofi September 12, 2019 5:01 PM - SEC Filing U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9 August 28, 2019 4:56 PM - PR NewsWire Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9 August 28, 2019 4:36 PM - StreetInsider Amgen (AMGN) patent on blockbuster Repatha drug invalid, judge rules - Bloomberg (REGN) August 28, 2019 3:05 PM - StreetInsider Full Article List